Equities

Vineet Laboratories Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
VINEETLAB:NSI

Vineet Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)32.69
  • Today's Change0.00 / 0.00%
  • Shares traded108.34k
  • 1 Year change-9.07%
  • Beta0.6393
Data delayed at least 15 minutes, as of Feb 18 2026 09:03 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Vineet Laboratories Ltd's revenues fell -50.20% from 1.51bn to 749.95m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a gain of 10.27m to a loss of 201.91m.
Gross margin4.86%
Net profit margin-29.27%
Operating margin-24.92%
Return on assets-16.94%
Return on equity-74.23%
Return on investment-54.66%
More ▼

Cash flow in INRView more

In 2025, Vineet Laboratories Ltd increased its cash reserves by 34.68%, or 790.00k. The company earned 114.91m from its operations for a Cash Flow Margin of 15.32%. In addition the company used 31.82m on investing activities and also paid 82.30m in financing cash flows.
Cash flow per share-12.94
Price/Cash flow per share--
Book value per share13.02
Tangible book value per share13.02
More ▼

Balance sheet in INRView more

Vineet Laboratories Ltd has a Debt to Total Capital ratio of 75.05%, a higher figure than the previous year's 15.54%.
Current ratio0.9533
Quick ratio0.1186
Total debt/total equity3.01
Total debt/total capital0.7505
More ▼

Growth rates in INR

Year on year, growth in earnings per share excluding extraordinary items dropped -2,065.82%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
-309.77
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.